Prospective Sinonasal Cancer Multi-institution Study

Status Recruiting

Clinical Trial Summary

This is a multi-institution prospective study of patients with sinonasal malignancies. The goal of this study is to learn more about the course of sinonasal cancer, treatment outcomes, and patient quality of life. In addition, central mutational and genomic analysis of tumor tissue will be evaluated.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Sinonasal Carcinoma

Clinical Trial Details

NCT number	NCT04755855
Study type	Observational
Source	Mayo Clinic
Contact	Marissa Larson
Phone	(507) 216-4999
Email	larson.marissa@mayo.edu
Status	Recruiting
Phase
Start date	January 1, 2021
Completion date	January 2031

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05151588` - Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma	Phase 2
Completed	`NCT04788264` - Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment	N/A
Active, not recruiting	`NCT03082534` - Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma	Phase 2
Active, not recruiting	`NCT01586767` - Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy	N/A
Recruiting	`NCT03942380` - Cell-free Tumor DNA in Head and Neck Cancer Patients	N/A
Recruiting	`NCT04979000` - HPV in Sinonasal Ca: Retrospective Analysis Association of Human Papilloma Virus (HPV) Serology and Behavioral Risk Factors
No longer available	`NCT03874455` - Tazemetostat Expanded Access Program for Adults With Solid Tumors